Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > ARCHIVE
ARCHIVE
- Astellas Applies for Darexaban in Japan
October 11, 2010
- Daiichi Sankyo Espha Aims at Sales of ¥5 Bil. in 1st Year
October 11, 2010
- Asthma Should Be Treated First in COPD Patients with Asthma: Prof. Nagai
October 11, 2010
- Daiichi Sankyo Completes Tender Offer for Zenotech Lab
October 4, 2010
- FDA Accepts NDA for Aricept Transdermal Patch: Eisai, Teikoku Seiyaku
October 4, 2010
- Takara Bio to Obtain Anticancer Agent from M's Science
October 4, 2010
- Japan's Own COI Disclosure System Necessary: Mr Hirai
October 4, 2010
- FDA Advisory Committee Not Recommend Approval for Lorcaserin: Eisai
October 4, 2010
- Kyowa Kirin Begins PIIb Trial for KW-0761 in Japan
October 4, 2010
- 2.4 Mil. Patients Suffer from Lumbar Canal Stenosis in Japan
October 4, 2010
- AnGes MG to Conduct Additional Trial for Collategene
October 4, 2010
- Peretinoin Reduces Risk of HCC Recurrence after Curative Therapy: Kowa
October 4, 2010
- New Anti-Epileptic Drug E Keppra: Otsuka, UCB
October 4, 2010
- NBI to Withdraw Alotec in Japan
October 4, 2010
- Pletaal Reduces Risk of Stroke, Hemorrhage in Japanese CI Patients: Otsuka
October 4, 2010
- ARB + CCB Combination Micamlo for Hypertension: NBI, Astellas
October 4, 2010
- Covance to Jointly Operate Central Lab with BML in Japan
October 4, 2010
- Dosing of Taspoglutide Suspended in PIII Due to Adverse Reactions: Roche
October 4, 2010
- Japan's Second mTOR Inhibitor Torisel: Pfizer
October 4, 2010
- 46th EASD Annual Meeting Highlights GLP-1 Agonists, DPP-4 Inhibitors
October 4, 2010
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…